Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Gyre Therapeutics (GYRE) over the last 14 years, with Q3 2025 value amounting to $15.8 million.

  • Gyre Therapeutics' Non-cash Items fell 1166.88% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year decrease of 1166.88%. This contributed to the annual value of $190.4 million for FY2024, which is 5714.13% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Non-cash Items is $15.8 million, which was down 1166.88% from $15.6 million recorded in Q2 2025.
  • Gyre Therapeutics' Non-cash Items' 5-year high stood at $444.2 million during Q4 2023, with a 5-year trough of $1.2 million in Q1 2021.
  • In the last 5 years, Gyre Therapeutics' Non-cash Items had a median value of $7.6 million in 2023 and averaged $41.3 million.
  • Per our database at Business Quant, Gyre Therapeutics' Non-cash Items crashed by 8520.66% in 2021 and then surged by 340672.61% in 2023.
  • Over the past 5 years, Gyre Therapeutics' Non-cash Items (Quarter) stood at $1.5 million in 2021, then skyrocketed by 737.19% to $12.7 million in 2022, then skyrocketed by 3406.73% to $444.2 million in 2023, then tumbled by 57.14% to $190.4 million in 2024, then tumbled by 91.71% to $15.8 million in 2025.
  • Its last three reported values are $15.8 million in Q3 2025, $15.6 million for Q2 2025, and $16.2 million during Q1 2025.